Oramed Pharmaceuticals (ORMP) Non-Current Assets (2011 - 2026)

Oramed Pharmaceuticals has reported Non-Current Assets for 16 years, with the latest figure at $200.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 1149.44% year-over-year to $200.7 million; the trailing twelve-month figure through Mar 2026 stood at $200.7 million (up 1149.44% YoY), and the FY2025 full-year result was $97.6 million, up 709.43% from the prior year.
• Non-Current Assets for Q1 2026 stood at $200.7 million, up from $97.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $200.7 million in Q1 2026, with the low at $4.3 million in Q3 2022.
• Historically, Non-Current Assets has averaged $43.6 million across 5 years, with a median of $27.4 million in 2022.
• The largest YoY upside for Non-Current Assets was 1193.97% in 2023 against a maximum downside of 83.87% in 2023.
• Oramed Pharmaceuticals' Non-Current Assets stood at $4.5 million in 2022, then surged by 1178.78% to $58.0 million in 2023, then plunged by 79.2% to $12.1 million in 2024, then soared by 709.43% to $97.6 million in 2025, then soared by 105.65% to $200.7 million in 2026.
• The last three Non-Current Assets figures came in at $200.7 million (Q1 2026), $97.6 million (Q4 2025), and $84.4 million (Q3 2025), per Business Quant data.